tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Insulin'

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Written by Ι Stock Market Media — February 8, 2016

Johnson & Johnson, like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, Johnson & Johnson’s head of global innovation, said that his company’s recent decision to partner with a privately held San Diego biotech was to “hedge our bets to make sure we would win in this space.” Johnson & Johnson’s deal with ViaCyte, Inc. is an effort to ...

Read More →
0

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0

PharmaCyte Biotech Releases Video Highlighting Diabetes Treatment Development Program

PharmaCyte Biotech Releases Video Highlighting Diabetes Treatment Development Program

SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media Group to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte’s story related to the development of its treatment ...

Read More →
0

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

Written by Ι Stock Market Media — May 20, 2015

PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science – bring together an international group of leading experts to work on one project. The project that is drawing their interest is PharmaCyte Biotech’s diabetes treatment and getting it into the hands of insulin-dependent patients around the world. These experts have become known collectively as the “International Diabetes Consortium,” and if PharmaCyte is to be successful, it will ...

Read More →
0

Nuvilex, Inc., Johnson & Johnson, and Medtronic, Inc., All Developing Type of “Artificial Pancreas” for Diabetics

Nuvilex, Inc., Johnson & Johnson, and Medtronic, Inc., All Developing Type of “Artificial Pancreas” for Diabetics

Written by ι Stock Market Media Group Staff — July 2, 2013

While Medtronic, Inc. (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are developing devices that can essentially act as a type of “artificial pancreas,” Nuvilex, Inc.’s (OTCQB: NVLX) unique cell encapsulation technology has shown it too can develop a type of “artificial pancreas” in preclinical diabetes studies.  Their approaches couldn’t be more different; however, all three companies are convinced that developing an artificial pancreas offers diabetics the best solution to ...

Read More →
0
ContactUs.com